Diagnostic Imaging's editors work hard to make the magazine engaging, but inevitably the conversation is a bit one-sided. We hope to change that for one night this month, with a Diagnostic Imaging Symposium: Strategic Outlook on Radiology's Future.
Diagnostic Imaging's editors work hard to make the magazine engaging, but inevitably the conversation is a bit one-sided. We hope to change that for one night this month, with a Diagnostic Imaging Symposium: Strategic Outlook on Radiology's Future.
This event is a rare opportunity to hear directly from some of the brightest thinkers in the specialty. Our speakers are tasked with describing trends that will shape imaging practice in the coming years-economics, politics, clinical advances, and technology and workflow-and offering strategies to make the most of them as individuals, practice groups, and as a specialty.
Regardless of subspecialty or practice style, the symposium should capture your interest. Dr. Sanjiv Gambhir of Stanford University's molecular imaging program will discuss the evolution of oncology imaging across modalities and into the molecular arena. Dr. Tom Brady from Massachusetts General Hospital will outline radiology's role in the transformation of cardiovascular imaging. Dr. Elliot Fishman from Johns Hopkins will map techniques for interpreting and managing volume data sets. Dr. Eliot Siegel from the Maryland VA will describe workflow technologies and techniques to improve daily practice. The end result, we hope, will be clear steps that can help our guests prepare themselves and their practices to succeed in an evolving medical environment.
Please join us Monday, Nov. 28, at the Millennium Knickerbocker Hotel in Chicago. There is no charge for this dinner event, but space is limited. Visit www. cmellc. com/disymposia to register or call (800) 447-4474. We hope to see you there!
Ms. Lowers is special projects editor for Diagnostic Imaging.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.